Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has shared an update.
Roquefort Therapeutics PLC has entered into a binding exclusive license agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. for the worldwide rights to AO-252, a first-in-class drug targeting TACC3 protein in multiple cancers. The agreement involves a reverse takeover and a proposed name change to Coiled Therapeutics PLC. The transaction includes an equity placing to raise funds for clinical trials and operational expansion. This strategic move aims to enhance Roquefort’s market position by advancing AO-252 through clinical stages, potentially benefiting up to 350,000 patients in the US and Europe, and achieving significant value milestones.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on clinical-stage oncology assets. The company is involved in developing novel cancer therapies, with a market focus on innovative treatments targeting proteins over-expressed in multiple cancers.
Average Trading Volume: 2,165,999
Technical Sentiment Signal: Sell
Current Market Cap: £2.6M
For detailed information about ROQ stock, go to TipRanks’ Stock Analysis page.